Rainbow Children Medicare IPO Basis of Allotment

^As certified by Madhu Mantri and Associates, Chartered Accountants, in their certificate dated May 2, 2022.

The Offer was made through the Book Building Process, in terms of Rules 19(2)(b) of the SCRR, read with Regulation 31 of the SEBI ICDR Regulations, and in compliance with Regulation 6(1) of the SEBI ICDR Regulations, therein not more than 50% of the Net Offer was available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs" and such portion, the "QIB Portion"), provided that our Company, Dr. Ramesh Kancharta (acting on behalf of the other Promoter Selling Shareholders and the Other Selling Shareholder) and the Investor Selling Shareholders may, in consultation with the BRLMs, allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis (the "Anchor Investor Portion"), of which one-third was reserved for domestic Mutual Funds, subject to valid Bids having been received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. Further, 5% of the Net QIB Portion was made available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion was made available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids having been received at or above the Offer Price. Further, not less than 15% of the Net Offer was made available for allocation to Non-Institutional Bidders ('Non-institutional Portion') of which one-third of the Non-Institutional Portion was made available for allocation to Bidders with an application size of more than Rs. 200,000 and up to Rs. 1,000,000 and two-thirds of the Non-Institutional Portion was made available for allocation to Bidders with an application size of more than Rs. 1,000,000 and under-subscription in either of these two subcategories of Non-Institutional Portion was allocated to Bidders in the other sub-category of Non-Institutional Portion, and not less than 35% of the Net Offer was made available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All potential Bidders, other than Anchor investors, were required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts and UPI ID (in case of Retail Individual Bidders using UPI Mechanism), if applicable, in which the corresponding Bid Amounts was blocked by the self-certified syndicate banks ("SCSBs") or under the UPI Mechanism, as applicable to participate in the Offer Anchor Investors were not permitted to participate in the Anchor Investor Portion through the ASBA process See "Offer Procedure" on page 523 of the Prospectus.

The bidding for Anchor Investor opened and closed on Tuesday April 26, 2022. The Company received 36 applications from 23 anchor investors for 8,878,896 Equity Shares. The Anchor Investor Offer Price was finalized at Rs. 542 per Equity Share. A total of 8,663,404 Equity Shares were allocated under the Anchor Investor Portion aggregating to Rs. 4,695,564,968.

The Offer received 254,335 applications for 257,733,603 Equity Shares (inducing applications from Anchor Investors and prior to technical rejections) resulting in Rs. 8.8331 times subscription. The details of the applications received In the Offer from various categories are as under (before technical rejections):

Final Demand

A summary of the final demand as at different Bid prices is as under

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being NSE on May 5, 2022

INVESTORS. PLEASE NOTE

The Employee Reservation as per the Prospectus was mentioned in amount terms aggregating to not more than Rs. 156.60 million, translating to 300,000 Equity Shares at Rs. 522 per Equity Share (after Employee discount of Rs. 20 per Equity Share). Valid Bids received and considered for Allotment under Employee Category were for 44,118 Equity Scares amounting to Rs. 23.02 million. The unsubscribed portion was adjusted as follows:

** Unsubscribed portion of Employee Reservation Portion of 246,440 Equity Shares spilled over to QIBs, NIB and Retail Categories in the ratio of 50:15:35.

Unsubscribed portion of 2,261,648 Equity Shares spitted over to QIB and NIB Categories in the ratio of 50.15

*1 additional Equity Share has been allotted to Category 1,836 in the ratio of 67:81

*1 additional Equity Share has been allotted to Category 1,863 in the ratio of 19:73

Unsubscribed portion of 246,440 Equity Shares spited over to QIBs NIB and Retail Categories in the ratio of 50:15:35.

The IPO Committee o(our Company on May 5, 2022, has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being NSE and has allotted the Equity Shares to various successful Bidders. The Allotment Advice-cum-Unblocking Intimations and/ or notices has been emailed or dispatched to the address of the investors as registered with the depositories. Further, the instructions to the Self Certified Syndicate Banks for unblocking of funds, transfer to Pubic Offer Account has been issued on May 5, 2022, and payment to non-Syndicate brokers have been issued on May 6, 2022. In case the same is not received within ten days, investors may contact the Registrar to the Offer at the address given below. The Equity Shares Allotted to the successful Allottees have been uploaded on May 6, 2022 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company has filed the Listing application with NSE and BSE on May 6, 2022. The Company has received listing and trading approval from NSE and BSE and the trading will commence on May 10, 2022.

Note All capitalized terms used and not specifically defined herein shall hare the same meaning as ascribed to them in the Prospectus.

INVESTORS, PLEASE NOTE

The details of the allotment made will be hosted on the website of the Registrar to the Offer, KFin Technologies Limited at: www.kfintech.com

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/ sole Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:

KFin Technologies Limited (formerly known as KFin Technologies Private Limited)

Selenium, Tower-B, Plot 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi - 500 032,

Telangana, India. Telephone: +914067162222

E-mail: rcml.ipo@kfintech.com

Website: www.kfintech.com

Investor Grievance ID: emward.ris@kfintech.com

Contact Person: M Murali Krishna

SEBI Registration Number: INR000000221

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF RAINBOW CHILDREN'S MEDICARE LIMITED.

RAINBOW CHILDREN'S MEDICARE LIMITED has filed the Prospectus dated May 2, 2022 with RoC and thereafter with SEBI and Stock Exchanges. The Prospectus is available on the website of SEBI at www.sebi.gov.in websites of BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively and is available on the websites of the BRLMs. i.e. Kotak Mahindra Capital Company Limited, J.P. Morgan India Private Limited and IIFL Securities Limited at https://investmentbank.kotak.com, www.jpmipt.com and www.iiftcap.com, respectively. Investors should note that investment in equity shares invokes a high degree of risk and for details relating to such risk, refer to the Prospectus, including the section titled 'Risk Factors' of the Prospectus. Specific attention of the investors is invited to 'Risk Factors' beginning on page 47 of the Prospectus.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act or any other applicable law of the United States and. unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined m Rule 144A under the U.S. Securities Act and referred to in this Prospectus as "U.S. QIBs" for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in this Prospectus as 'OIBs') pursuant to Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in offshore transactions in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.